These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

564 related articles for article (PubMed ID: 36471232)

  • 41. Ultrasonographic findings of metabolic dysfunction-associated fatty liver disease: A comparative study with non-alcoholic fatty liver disease and clinical characteristics.
    Song BG; Kang TW; Sinn DH; Kim YY; Min JH; Hwang JA; Shin J
    Clin Imaging; 2024 Apr; 108():110097. PubMed ID: 38310832
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Metabolic Dysfunction-Associated Fatty Liver Disease and Incident Cardiovascular Disease Risk: A Nationwide Cohort Study.
    Lee H; Lee YH; Kim SU; Kim HC
    Clin Gastroenterol Hepatol; 2021 Oct; 19(10):2138-2147.e10. PubMed ID: 33348045
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease.
    Fan H; Li L; Liu Z; Zhang P; Wu S; Han X; Chen X; Suo C; Cao L; Zhang T
    BMC Gastroenterol; 2023 Jan; 23(1):3. PubMed ID: 36604612
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Fatty liver index predicts incident risk of prediabetes, type 2 diabetes and non-alcoholic fatty liver disease (NAFLD).
    Cuthbertson DJ; Koskinen J; Brown E; Magnussen CG; Hutri-Kähönen N; Sabin M; Tossavainen P; Jokinen E; Laitinen T; Viikari J; Raitakari OT; Juonala M
    Ann Med; 2021 Dec; 53(1):1256-1264. PubMed ID: 34309471
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
    World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Estimation of gamma-glutamyl transferase as a suitable simple biomarker of the cardiovascular risk in children with non-alcoholic fatty liver disease.
    Bobrus-Chociej A; Flisiak-Jackiewicz M; Daniluk U; Wojtkowska M; Kłusek-Oksiuta M; Tarasów E; Lebensztejn D
    Acta Biochim Pol; 2018 Oct; 65(4):539-544. PubMed ID: 30380561
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Utility of Indices Obtained during Medical Checkups for Predicting Fatty Liver Disease in Non-obese People.
    Otsubo N; Fukuda T; Cho G; Ishibashi F; Yamada T; Monzen K
    Intern Med; 2023 Aug; 62(16):2307-2319. PubMed ID: 36517035
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.
    Staufer K; Huber-Schönauer U; Strebinger G; Pimingstorfer P; Suesse S; Scherzer TM; Paulweber B; Ferenci P; Stimpfl T; Yegles M; Datz C; Trauner M
    J Hepatol; 2022 Oct; 77(4):918-930. PubMed ID: 35605744
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic Dysfunction-Associated Fatty Liver Disease Predicts Long-term Mortality and Cardiovascular Disease.
    Moon JH; Kim W; Koo BK; Cho NH;
    Gut Liver; 2022 May; 16(3):433-442. PubMed ID: 34635626
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Metabolic dysfunction associated fatty liver disease: The new nomenclature and its impact.
    Tang SY; Tan JS; Pang XZ; Lee GH
    World J Gastroenterol; 2023 Jan; 29(3):549-560. PubMed ID: 36688021
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non-invasive score.
    Xin Z; Zhu Y; Wang S; Liu S; Xu M; Wang T; Lu J; Chen Y; Zhao Z; Wang W; Ning G; Bi Y; Xu Y; Li M
    Liver Int; 2020 Apr; 40(4):806-814. PubMed ID: 31820847
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Non-obese non-alcoholic fatty liver disease (NAFLD) in Asia: an international registry study.
    Tan EX; Lee JW; Jumat NH; Chan WK; Treeprasertsuk S; Goh GB; Fan JG; Song MJ; Charatcharoenwitthaya P; Duseja A; Imajo K; Nakajima A; Seki Y; Kasama K; Kakizaki S; Lesmana LA; Zheng KI; Zheng MH; Koh CJ; Ho KY; Goh KL; Wong VW; Dan YY
    Metabolism; 2022 Jan; 126():154911. PubMed ID: 34648769
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population.
    Lee H; Lim TS; Kim SU; Kim HC
    Hepatol Int; 2022 Dec; 16(6):1308-1317. PubMed ID: 36070124
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Type 2 diabetes mellitus in metabolic-associated fatty liver disease vs. type 2 diabetes mellitus non-alcoholic fatty liver disease: a longitudinal cohort analysis.
    Muthiah M; Ng CH; Chan KE; Fu CE; Lim WH; Tan DJH; Nah B; Kong G; Xiao J; Yong JN; Tan B; Syn N; Wang JW; Sayed N; Tan E; Chew NW; Dan YY; Siddiqui MS; Sanyal AJ; Noureddin M
    Ann Hepatol; 2023; 28(1):100762. PubMed ID: 36182031
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Moderate alcohol consumption is not associated with subclinical cardiovascular damage but with hepatic fibrosis in non-alcoholic fatty liver disease.
    Kashiwagi K; Yamaguchi A; Shiba S; Taniki N; Inoue N; Takaishi H; Iwao Y; Kanai T
    Alcohol; 2020 Dec; 89():1-7. PubMed ID: 32738385
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Metabolic-associated fatty liver disease and the risk of cardiovascular disease.
    Zhang P; Dong X; Zhang W; Wang S; Chen C; Tang J; You Y; Hu S; Zhang S; Wang C; Wen W; Zhou M; Tan T; Qi G; Li L; Wang M
    Clin Res Hepatol Gastroenterol; 2023 Jan; 47(1):102063. PubMed ID: 36494073
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease from clinical to pathological characteristics: a multi-center cross-sectional study in real world.
    Li Y; Dai C; Ruan Y; Yang H; Zeng H; Huang R; Wang J; Dai M; Hao J; Wang L; Li J; Yan X; Lu Z; Ji F
    Postgrad Med J; 2024 Apr; 100(1183):319-326. PubMed ID: 38272486
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan.
    Yoneda M; Yamamoto T; Honda Y; Imajo K; Ogawa Y; Kessoku T; Kobayashi T; Nogami A; Higurashi T; Kato S; Hosono K; Saito S; Nakajima A
    J Gastroenterol; 2021 Nov; 56(11):1022-1032. PubMed ID: 34601620
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease.
    Tanaka M; Mori K; Takahashi S; Higashiura Y; Ohnishi H; Hanawa N; Furuhashi M
    Nephrol Dial Transplant; 2023 Feb; 38(3):700-711. PubMed ID: 35612975
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nonalcoholic fatty liver disease or metabolic dysfunction-associated fatty liver disease diagnoses and cardiovascular diseases: From epidemiology to drug approaches.
    Dongiovanni P; Paolini E; Corsini A; Sirtori CR; Ruscica M
    Eur J Clin Invest; 2021 Jul; 51(7):e13519. PubMed ID: 33583033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.